Recognized for end-to-end value chain coverage, AI-enhanced manufacturing capabilities and sustained investment in AI-driven engineering

June 18, 2026 - Cognizant today announced that it has been recognized as a Leader in Avasant’s Life Sciences Digital Services 2026 RadarView™. The placement reflects Cognizant’s depth of capability across the life sciences value chain and its continued investment in AI, advanced engineering and ecosystem partnerships that enable pharmaceutical, biotech and medical device enterprises to accelerate innovation from discovery to patient delivery. As an AI builder, Cognizant is helping clients turn AI ambition into enterprise value through full-stack solutions built for industry-specific needs.

As life sciences companies face mounting pressure to improve patient outcomes, accelerate time to market, manage costs and respond to evolving regulatory requirements, innovation is becoming an increasingly important business priority. Embedding digital transformation into enterprise strategy can help organizations operate more efficiently, make more informed decisions and build more agile, connected businesses. The report highlights how service providers are supporting the industry in areas such as R&D efficiency, genomics-enabled precision medicine, manufacturing resilience and the evolving demands of payors and market access. Cognizant helps clients meet these challenges by shaping and executing digital strategies that accelerate scientific progress and translate into tangible business value.

As part of their research, Avasant evaluated 43 service providers and recognized 7 as leaders based on value delivered to the market over the past 12 months. Providers were assessed across two key dimensions—practice maturity and future-proofing—with the resulting analysis categorizing them as leaders, innovators, disruptors, challengers or tech pioneers. Cognizant earned the highest rating in both practice maturity and future-proofing, positioning it as the highest ranked service provider in the Leader category.

Strength across the life sciences value chain

“Cognizant supports life sciences enterprises through its capabilities spanning R&D, clinical development, regulatory, manufacturing and commercial functions. Its offerings include AI-enabled platforms for hit discovery, molecular design and biomarker identification, as well as clinical data management, trial analytics and regulatory automation, integrated with platforms such as Veeva Vault. In manufacturing, it delivers AI-enhanced MES frameworks, real-time shopfloor visibility and digital production systems to support compliant, agile operations. Its solutions, including LabVue, ODIN and OptiTech, enable data integration, laboratory management and automation across supply chain and production workflows,” said Samkit Jain, Lead Analyst at Avasant.

This breadth reflects how Cognizant embeds AI directly into each life sciences function rather than treating it as a separate, bolt-on layer. By connecting scientific, operational and patient data from early discovery through commercial operations, the company helps enterprises make faster decisions, cut manual effort and bring new capabilities to scale as priorities shift.

A connected partner ecosystem

Cognizant’s leadership is underpinned by a broad ecosystem of technology and platform partners spanning the discovery, regulatory and pharmacovigilance landscape. Integrations with industry systems such as Veeva Vault, alongside collaborations across leading cloud providers, give clients secure and scalable foundations for clinical, quality and commercial workflows—speeding deployment while helping safeguard the data integrity and regulatory rigor the sector depends on. Cognizant also works closely with technology leaders, including Microsoft Azure, SAP, Oracle and Salesforce, supporting enterprise-scale AI transformation, cloud-native innovation and CRM-integrated sales enablement.

Investing in the future of life sciences

Cognizant has developed a 6,500 sq. ft. Health Sciences Innovation Center in Chennai designed to support the future of healthcare and life sciences, fostering unencumbered innovation for organizations worldwide. The center offers distinct zones designed to represent the entire health sciences value chain aiming to support clients and partners to explore, prototype and implement forward-looking solutions to complex industry challenges. Its purposefully designed spaces foster creativity, experimentation and focused innovation—free from traditional constraints and distractions.

It continues to invest in next-generation capabilities for the industry, including a $1 billion commitment to generative AI, its Flowsource™ platform and Neuro^® AI decisioning suite for multi-agent orchestration and a global network of AI Innovation Studios. “Cognizant’s continued investments in AI-driven engineering, multi-agent orchestration and cloud partnerships, combined with its end-to-end coverage across the life sciences value chain, have strengthened its positioning as a Leader in Avasant’s Life Sciences Digital Services 2026 RadarView,” said Samkit Jain, Lead Analyst at Avasant.

“At Cognizant, we are helping life sciences organizations turn AI and digital innovation into enterprise value—accelerating time to market, strengthening manufacturing resilience and improving patient access across the value chain,” said Mohammad Haque, Head of Intelligent Enterprise Platforms & Large Deals at Cognizant. “As an AI builder, we combine deep industry expertise with engineering strength to build full-stack AI solutions that reflect each client’s unique context and help them move from experimentation to scaled impact. Being recognized as a Leader in Avasant’s Life Sciences Digital Services 2026 RadarView affirms the strength of our end-to-end capabilities and our commitment to engineering the future of healthcare alongside our clients and partners.”

Read the full report HERE.